Category Archives: Nano Medicine

Over the past decade, healthcare has been aggressively organizing to use data for better medical care. Healthcare professionals today are routinely using electronic health records (EHRs) to improve their ability to diagnose medical conditions, at the same time reducing and even preventing medical errors for better patient outcomes.

Medical tablets and touchscreen PCs provide the portals into that data. Medical equipment manufacturers collaborate with both hardware and software providers to bring their solutions to the healthcare market, positively impacting patients and providers alike.

In the past, doctors recorded patient information with a pen and clipboard and stored patient files in office filing cabinets. In the mid-2000s, HIPPA and other healthcare regulators made it a requirement to keep electronic medical records (EMRs), also called electronic health records (EHRs). The final deadline for healthcare organizations to switch from paper records to electronic records was in 2014.

For a few years, clinicians continued gathering patient data on paper, and inputting that data into a computer. The transfer of data was sometimes sloppy and inaccurate, and it was a time-consuming process. But then healthcare systems began placing computers at the point of care, to skip the pen and clipboard all together. Now, according to a national survey of doctors cited on the HealthIT.gov website:

Mobile computers and computers installed at the point of care are enabling medical professionals to acquire a wealth of data on their patients and improve their care. The benefits of EHRs can include the ability to manipulate data that can detect problems with the patients health and in the hospital or clinics operational system.

Medical computers are designed to stand up to harsh, medical-grade cleaners.

Medical touchscreen PCs allow providers to deliver continuity of care, manage risk and prevent liability, but not just any computing device can enter a healthcare environment. Computers used in hospitals and other medical facilities must meet patient needs, safety requirements and the strict demands of the field.

While the requirements can vary drastically depending on the application, there are several standard features for use in a healthcare setting.

Provide the basics. The medical-grade touchscreen PC must have basic functionality: processing speed, storage, inputs and outputs, and the ability to securely connect to a wireless or wired network to allow various medical providersbut not unauthorized users to access patient records.

Reliability. Healthcare never stops, so in hospitals, medical-grade touchscreen PCs must be able to run 24/7/365 and therefore have the same ruggedness as those units used in the rough world of manufacturing. Reliability is crucial in a demanding healthcare setting, which, of course, is one place where reliability can mean life or death.

Compliance. Does the computer support HIPPA-compliant EHR practices, and is it compatible with the manufacturers current operating system and software? There are a lot of compliance measures for medical devices to ensure they are secure and reliable.

Most electronic devices used in medical facilities must carry certifications regarding electrical charge and flow from the device. Some of the common certifications are CE, FCC class A or B, UL60601-1, EN60601-1 and IEC60601-1. 60601-1 certification is the core certification pertaining to the placement of computers near patients or sensitive equipment.

Medical computers also need to have sterile and easy-to-clean bezels. Though computers may seem clean, bacteria, undetectable to the human eye, can easily build up. Standard PCs are not sterile enough for a hospital or other healthcare environment. Medical computers are designed with minimal cracks and crevices to deny hiding places for bacteria to grow. Flush-front designs also make it easy to wipe down the computer between patient visits or surgeries.

Medical computers are built with special antibacterial plastic, or they can have antibacterial coatings that impede the growth of bacteria and germs. The plastic housing is also designed to stand up to harsh, medical-grade cleaners that can degrade and damage the bezel of non-medical-grade computers.

OEM projects have special requirements not typically seen in standard medical computer deployments.

Fanless cooling. Fans can build up dust and debris, leading to early computer failure. They are also a common point of failure on mobile computers that are bumped or moved around often. Fanless cooling systems dont push around dust or germs and they allow the computer to run silently.

Fully sealed enclosures. These are easy to clean with sanitizer and dont allow moisture to invade the inside of the PC.

Antimicrobial touchscreen and enclosure. Antimicrobial plastic or coating prevents the spread of Methicillin-resistant Staphylococcus aureus (MRSA) and other infections by 95%.

Carefully selected I/Os. Standard computers are not designed with medical applications in mind. They can lack important I/Os (inputs and outputs) that are used to connect the computer with common medical devices and peripherals, and they may include irrelevant I/Os that usually go unused in healthcare.

Long life. To meet the demands of medical settings, touchscreens should have a useful life of 100 million touches, and both the internal and external components of the computer need to last (usually a minimum of five years). Installing new computer hardware in a healthcare facility or hospital is a costly undertaking that can take months or even years. So, it is all the important that the computers are built to last.

Mounting design. Units with standard VESA mounts allow easy and reliable attachment to your equipment or system. Some OEM medical machines require a panel-mount or open-frame computer. Medical tablet PCs typically come with a docking station for drop-and-go charging, and sometimes require a customized mounting solution for OEM devices.

Surge protection. Computers that are directly connected to a patient must have surge protection, lest they interfere with the patient or other medical equipment. The best way to protect the patient is to outfit the input/output ports with 4kV isolation, which is accounted for under the IEC60601-1 4th Edition Certification.

Security. It is vital that hospitals protect patient records to satisfy multiple government standards. To ensure a fully secure computing environment, computers used in healthcare should come equipped with a Trusted Platform Module (TPM). The TPM serves as a hardware authentication tool to be used in conjunction with software-based security solutions. TPM is widely considered to be the safest form of computer security and is trusted to keep patient records private.

Though medicine has been using PC touchscreens for the past 30 years, you can imagine how far weve come, particularly recently. Wireless technology has benefited both computer carts and stationary equipment using touchscreens, particularly with facilities using booster devices and mesh systems.

With the advent of hot-swappable batteries, clinicians now have the option of unplugging the AIO computer from a power source and moving to the next room without restriction. Battery-powered computers now come in 21.5 in. and 23.8 in. and can run up to eight hours without needing to be plugged into power.

As for operating systems, Android isnt just for smartphones. Thanks to the flexibility offered by this operating system, computers will function successfully with a variety of systems used in a healthcare facility. Plus, Android gives equipment designers a high level of flexibility when it comes to device functionality.

Android provides the flexibility that healthcare, which is always evolving, needs. The operating system makes medical-grade computers even more appealing to developers, who can easily customize applications to accommodate unique I/O devices and create GUIs to manage any medical need.

Android medical-grade computers do not require additional storage capacity and memory requirements that are necessary for Window-based computers. The significant cost savings associated with these differences are driving medical applications towards Android-based computing.

Size is also making a difference. Manufacturers are providing smaller, slimmer, lighter-weight computers that are better able to move around a facility, as cart-mounted computers on wheels (COWs). Mobile computing devices continue to get smaller, too. Medical tablets are easy to carry around and handheld devices can fit into the pocket of a white coat.

As components are shrinking, this compactness (combined with durability) enables these units to go wherever clinicians go. When mounted, these computers take up less room on COWs or in equipment, yet the screens are very readable and available in large-enough sizes for DICOM imaging and medical chart or image reading.

Computers installed at the point of care enable medical professionals to collect a wealth of data.

Original equipment manufacturer (OEM) projects have special requirements that arent typically seen in standard medical computer deployments. This process is best explained with an example.

In 2017, a medical OEM was searching for a computer with 60601-1 certification, a PCIe slot for a graphics card and an anti-bacterial enclosure. The computer would be used with the OEMs autonomous tissue removal robot that treats lower urinary tract symptoms due to BPH (enlarged prostate). They tested a 21.5-in., medically certified, all-in-one touchscreen computer from Teguar.

After the OEM approved the medical computer in terms of hardware performance, the researchers used the device in clinical trials outside the United States. After a couple of years of successful trials abroad, which included a 181-patient, double-blind, randomized clinical trial, the technology for the treatment of prostate disease gained approval by the FDA for access to the U.S. market.

Throughout the whole process, in this case several years, the OEM and the computer manufacturer must communicate clearly and timely, as to not delay any aspect of the project. Over that time, a consumer-grade computer model will undergo several upgrades, or even be discontinued for a newer model. Medical devices are certified to their exact specs, so the computer cannot simply be switched out for the newer model. This is where a long life cycle is essential. The CPU used in this computer was on Intels embedded roadmap, ensuring that it will be available from Intel for more than 10 years.

Today, the manufacturer has deployed about 150 of its autonomous tissue removal robots. They are creating a better healthcare experience for patients by reducing the invasiveness of the surgery and minimizing the commonly experienced complications in current methods for the removal of prostatic tissue. Over the next few years, the device manufacturer expects the device to gain traction in terms of deployment and market use.

This collaboration has been successful because the computer used in this project provided a forward-looking solution. The computer met the project needs at the time and in the future, in terms of spec requirements, but also would meet the stringent FDA requirements.

Jacob Valdez is a sales manager at Teguar Computers, a Charlotte, N.C. provider of industrial and medical PCs.

View original post here:
Medical Computers Impact the Standard of Care - Machine Design

KANAZAWA, Japan, Feb. 10, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous system. The approach lies in combining two cancer drugs, with one compensating for a resistance side effect of the other.

In 20 40% of patients with cancer, metastasis (the development of secondary tumors) in the central nervous system (CNS) occurs. CNS metastatis impacts negatively on a patient's quality of life, and is associated with a poor health prognosis. In a form of cancer known as ALK-rearranged non-small-cell lung cancer (NSCLC), CNS metastatis is known to persist when drugs targeting primary tumors are used.Now, Seiji Yano from Kanazawa University and colleagues have investigated the origins for the resistence to such drugs, and tested a new therapeutic strategy on a mouse model.

The researchers looked at the drug alectinib.Although used in standard treatments for advanced ALK-rearranged NSCLC, approximately 20 30% of patients treated with alectinib develop CNS metastatis, which is attributed to acquired resistance to the drug.

By treating mice first injected with tumor cells with alectinib daily for 16 weeks, the scientists obtained a mouse model displaying alectinib resistance.By biochemical analyses of the mouse brains, Yano and colleagues were able to link the resistance to the activation of a protein known as epidermal growth factor receptor (EGFR).This activation is, in turn, a result of an increase in production of amphiregulin (AREG), a protein that binds to EGFR and in doing so 'activates' it.

Based on this insight, the researchers tested the effect of administering drugs used for inhibiting the action of EGFR in combination with alectinib treatment.The experiments showed that a combination treatment of alctinib with either erlotinib or osimertinib two existing EGFR-inibiting drugs prevented the progression of CNS metastasis, controlling the condition for over 30 days.

The scientists conclude that the combined use of alectinib and EGFR-inhibitors could overcome alectinib resistance in the mouse model of leptomeningeal carcinomatosis (LMC), a particular type of CNS metastasis.Quoting Yano and colleagues: "Our findings may provide rationale for clinical trials to investigate the effects of novel therapies dual-targeting ALK and EGFR in ALK-rearranged NSCLC with alectinib-resistant LMC."

Background

Non-small-cell lung cancer

Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer. 85% of all lung cancers are of the NSCLC type. NSCLCs are less sensitive to chemotherapy than SCLCs, making drug treatment of the highest importance.

Alectinib is a drug used for treating NSCLC, with good efficiency. However, 20-30% of patients taking the drug develop secondary cancer in the central nervous system (CNS), which is associated with an acquired resistance to alectinib.Seiji Yano from Kanazawa University and colleagues have now made progress towards a novel therapy against this resistance: a combination of alectinib with other drugs.

Epidermal growth factor receptor inhibitors

The drugs that Yano and colleagues tested in combination with alectinib on a mouse model were of a type known as epidermal growth factor receptor (EGFR) inhibitors, including osimertinib and erlotinib. Both are being used as medication for treating NSCLC.The former was approved in 2017 as cancer treatment by the U.S. Food and Drug Administration and the European Commission.Yano and colleagues obtained results showing that EGFR inhibitors counteract resistance to alectinib and have therefore potential in novel therapies for NSCLC and secondary cancers in the CNS.

Reference

Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, and Seiji Yano. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer, Journal of Thoracic Oncology, published online on January 21, 2020.

Story continues

DOI: 10.1016/j.jtho.2020.01.001

URL: https://www.sciencedirect.com/science/article/pii/S1556086420300228

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Further information

Hiroe Yoneda Vice Director of Public Affairs WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University Kakuma-machi, Kanazawa 920-1192, Japan Email: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81-(76)-234-4550

View original content:http://www.prnewswire.com/news-releases/kanazawa-university-research-combined-drug-treatment-for-lung-cancer-and-secondary-tumors-301001822.html

SOURCE Kanazawa University

Read more here:
Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance

PEORIA, Ill. (WMBD) Yes, the future is here. Its not by luck that were seeing extensive development happening and much of it in the innovation space, said Peoria Mayor Jim Ardis.

Virtual reality, energy from graphite, and using plants rather than plastic are three different themes for three different companies Mayor Ardis says will lead Peoria into a bright future.

Enduvo, a content authoring, and delivery platform removes the complexity and high cost associated with creating virtual reality and augmented reality training.

Pediatric Cardiologist, Dr. Matthew Bramlet, created Enduvo.

His developments utilize virtual reality in workforce training.

Enduvo reaches beyond the medical field, helping engineers and the United States military.

They can actually put their own experts into VR and create their own training modules that can convey complex flight patterns, terrain, engines or medic training, medical device training, Dr. Bramlet said.

Learn more about Enduvo here.

Natural Fiber Welding on Galena Road is working to use plants rather than plastics to create sustainable materials like later alternatives.

We have the potential, when this thing takes off, to replace a lot of the old textile jobs that were huge in this country that all left mostly to Mexico and China, said Peoria Mayor Jim Ardis.

Lastly, a nano-tech company called NTS has made groundbreaking devices like wireless sensors and GPS trackers.

NTS CEO Don Meyer says he wants to build his companys headquarters in Peoria.

We want to keep it at home. If we can do that, build a community like all these folks who are sitting up here are doing, thats the key, Meyer said.

The buzz of new business is centered by the new 9-block Innovation District downtown Peoria offering a place for startups and entrepreneurs to come and thrive.

Mayor Ardis announced Tuesday, the Peoria Innovation Alliance has helped Peoria secure the first North American competition for the Future Agro Challenge Startup Competition.

Hundreds of people will be in town mid-April to pitch their ideas for sustainability, agriculture production, and more.

The winner will advance to a competition in Greece with the chance to win $100,000 for their project.

Ardis emphasized that innovation isnt new to Peoria. He highlighted the work Caterpillar has been doing in the area for nearly a century.

For 50 years, the University of Illinois College of Medicine Peoria has done clinical research and collaborated with community partners all while educating future healthcare providers.

Ardis praised UnityPoint and OSF Healthcare for the investments those systems have made in the Peoria Area, employing about 16% of the workforce.

A high-profile developer was honored during Tuesdays address.

Kim Blickenstaff is this years recipient of the Mayors Outstanding Community Service Award.

Hes the financial force behind projects including revitalizing the Peoria Armory and transforming the Scottish Rite Cathedral into a concert hall.

Blickenstaff is also creating an outdoor resort in his hometown of Spring Bay and bring back the Al-Fresco Park.

He hopes bringing more visitors to the area will help them see what all Peoria has to offer.

Thats part of what were trying to do with the Scottish Rite, or the Scotty as you guys call it. You have the Ronald McDonald House down there as well. You got to invest to move forward, otherwise, things are always going to stay the same, Blickenstaff said.

Blickenstaff was behind the Betty Jayne Community Performing Arts Center which opened last August in Peoria Heights. He also broke ground on a boutique hotel in the Heights last May.

Continue reading here:
Bright light Peoria to be fueled by innovation, ground-breaking technology according to Mayor Jim Ardis - CIProud.com

The Wuhan Coronavirus has rapidly become a global health crisis and is producing hourly headlines. As a result, many of the vaccine tickers started to experience parabolic reactions as investors speculate on who will benefit from the growing health crisis. NanoViricides (NNVC) is one of these tickers and has rocketed from ~$3 to around $19 per share. On January 30th, NanoViricides announced it is has already initiated a program for developing a treatment for the 2019-nCOV." In addition, the company believes that their platform technology allows them to possibly have the most rapid pathway for new drug development against viral diseases. This triggered a sharp spike in the share price and has investors keeping a close eye on NNVC for their next move. Unfortunately, the company has yet to gain support from governmental and international agencies, so it doesnt appear NanoViricides is going to be in lead considering Moderna (MRNA) at least has a clinical collaboration with NIH. What is more, the company has started several pipeline programs but has yet to put one into human trials. Consequently, I believe investors need to be cautious around this ticker and should be skeptical about its ability to be a long-term investment.

I intend to provide a brief background on the companys platform technology and pipeline programs. In addition, I discuss my concerns around the companys technology and the ability to get one of their programs through the FDA. Moreover, I recap the companys history of publicizing their intention to develop a therapy for the latest outbreak but has yet to get one of these programs into the clinic.

NanoViricides is committed to the advancement of nanomedicine drugs in the battle against viruses. The companys nanoviricide platform technology intends to develop first-in-class drugs to envelope virus particles, which should block a virus from infecting a healthy cell and will eventually destroy the virus.

Figure 1: NanoViricide Mechanism of Action (Source: NNVC)

NanoViricides has its own c-GMP capable manufacturing facility that can be used to produce their own product candidates for both clinical and commercial use. In terms of pipeline programs, the company has multiple preclinical programs that are moving closer to an IND and into human trials (Figure 2).

Figure 2: NanoViricide Pipeline (Source: NNVC)

At the moment, the company is focused on bringing their NV-HHV-101 HerpeCide program into human trials. This would be the companys lead product candidate for a topical treatment for shingles rash and would be the companys first clinical program. According to the company, NV-HHV-101 had positive GLP Safety/Toxicology and non-GLP studies. Unfortunately, the company hasnt been able to produce any animal models in order to evaluate their dermal treatment but has been using ex vivo human skin organ culture model studies to determine some safety and efficacy. NanoViricides is preparing to file an IND and transition into a clinical-stage biotech.

Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 cold sores and of HSV-2 genital ulcers programs. In addition, the company has several preclinical programs that include therapies for HIV, Dengue, Ebola, Bird Flu. These programs are at different stages of preclinical development and have demonstrated safety in animal models. According to the company, their anti-HIV drug candidate has demonstrated complete suppression of the HIV virus in mouse models, which would lead to a functional cure.

My Concerns

Does the NanoViricide entice or attack a virus? After reading through the companys presentation, I couldnt come to a conclusion about how their platform works. The company has illustrated that their NanoViricides attacks and envelopes the virus (Figure 1). However, they have also stated that the NanoViricides fools the virus that it is a host cell and then entraps the virus. Perhaps the NanoViricides work both ways, but it still has me wondering about how it is supposed to act inside the bodya human host cell is astronomically bigger than the virus that is attempting to infect it (Figure 3).

Figure 3: Size Comparisons (Source: Research Gate)

Viruses are measured in nanometers and human cells are measured in microns, yet, the NanoViricide is attempting to trick the virus to thinking it is human cell. Indeed, a virus doesnt decide to attach to a human cell because of its size but rather surface receptors. Still, I dont see it as it being tricked but rather just getting stuck and consumed...which makes me wonder about the size of a NanoViricide...How big of a virus can it cover? Can multiple NanoViricides work on one virus?

How does the NanoViricide destroy the virus? Viruses are quite resilient for just being RNA or DNA encapsulated in a protein coat. A virus requires host cells to carry out the remaining life processes in order to reproduce. This gives our bodies a chance to identify and destroy viruses with our innate and adaptive immune systems by several complex mechanisms. So, an explanation of how a NanoViricide destroys a virus needs to go beyond it encapsulates and destroys. The company explains that the NanoViricide delivers a devastating payload of active pharmaceutical ingredients API into the virus particle, thereby completely destroying the enemy. What is this API? Does it cause cytotoxicity? Is it relying opsonization? The company has a slide (Figure 4), that shows NanoVircide dismantling the capsid.

Figure 4: NanoViricide Dismantling (Source: NNVC)

Admittedly, the company is attempting to be one of the leaders in nanomedicine, so perhaps the mechanisms are beyond me and contemporary medicine. Unfortunately, we cant rely on currently approved products or science to understand how NanoViricide works, which doesnt bode well in my opinion. Contemporary vaccines, antibodies, and anti-viral drugs are effective against viruses, so I have to imagine health agencies and organizations are going to side with the standard-of-care modalities rather than take a chance with unproven technology.

Another issue I have with their technology is how they plan to run clinical trials for some of their pipeline programs. Take their shingles cream candidate, which is intended to be a topical treatment for the shingles rash. How is the company supposed to run a clinical trial for this? What would be an inclusion or exclusion trial for this? How would they know if it is better at clearing up a rash vs. placebo alone? A shingles rash appears abruptly and can last several weeks, so, determining if NanoViricides were able to shorten or diminish the impact of the rash would be difficult to measure. I have the same issue with infectious viruses, where the company is attempting to prove their NanoViricides work against a dangerous virus. With vaccines, companies are able to determine their ability to stimulate the immune system and elicit some seroprotection without the subject being infected with the virus. NanoViricides is not a vaccine, so the subject would have to be infected with the Wuhan Coronavirus in order to determine if it is effective against the virus. Overall, I see the company having a hard time clearing some of these regulatory hurdles and being able to prove its product works the way it is intended.

The other concerning issue is the companys history of developing the current global health crisis and has yet to get that program into the clinic. The company started to develop an Avian Bird Flu drug back in 2006, and yet, it has yet to hit the clinic. The same can be said for their Dengue program that was started in 2007, and the same with Ebola in 2008 and 2014. In addition, the company promoted their efforts against MERS in 2014 and has been attempting an HIV program for several years. Unfortunately, none of these programs have made it into the clinic for human trials but investors cash has made it into the companys bank account. It appears the company takes advantage of any major global health crisis by claiming they have a potential product and they are working hard to quickly progress their NanoViricides against the most recent headline virus. In reality, the company doesnt move out of discovery and preclinical studies. Sadly, investors have been enticed by the prospects of investing in a company that has an answer to the current scare, only to experience dilution that has devastated the share price over the years (Figure 5).

Figure 5: NNVC Weekly Chart (Source: Trendspider)

Even if the company wanted to push forward with development and start human trials, it will need a large amount of cash to get the ball rolling. What is more, the company would most likely need to secure commercial partners to produce and distribute their products. Admittedly, the company just raised about $7.5M in a public offering after the stock popped once the Wuhan virus started to catch the publics eye. Still, the company will most likely need some additional funding to get one of their product candidates through the FDA.

NanoViricide might be working on a potential treatment for the Wuhan Coronavirus, but investors need to be cautious here. The company has a 15-year history of promoting their attempts to develop a leading therapy for the latest virus but has yet to get one of these programs into human trials. Even if the company is able to develop a potential candidate, it is going to need the help from government agencies and institutions to be used and it looks as if some of the worlds biggest pharmaceutical and biotechs are already starting to send some of their anti-viral products to China to help with the outbreak. In fact, Johnson & Johnson (JNJ) is already working on a vaccine and has donated some of their HIV medications. What is more, NanoViricides is not even listed on a CNBC list of companies working on a Coronavirus vaccine or drug (Figure 6).

Figure 6: List of Coronavirus Companies (Source: CNBC)

Considering these points, I would advise investors to wary of investing until the company is able to get an IND and reports their first human data. Until then, I expect shorts to start piling on once the market realizes the company is reusing its old playbook of promoting a program and never following through with it.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

More here:
NanoViricides: A History Of Producing Headlines Without Producing A Product - Seeking Alpha

Nanomedicine, refers to highly specific medical intervention at the molecular level for curing disease or repairing damaged tissues. Though in its infancy, could we be looking at the future of medicine? Early clinical trials certainly look promising.How Nanomedicine Works

- Nanomedicine works by injecting nanoparticles into the body- Can be used to:- Deliver medicine- Find and treat disease- Repair damaged cells

One human hair is approximately 80,000 nanometers wideApplications of Nanomedicine

- Drug Delivery- Using nanotechnology to deliver medicine, diabetic rats kept stable blood sugar levels for 10 days after injection- Cancer Diagnosis and Treatment- Using microRNA from a patient's blood plasma and nanotechnology:- Medical professionals can determine if lung cancer is present- Begin treatment the same day- Using Nano-Therm therapy to overheat brain cancer cells helps to destroy them- In clinical trials, those with recurrent glioblastoma survived a median of 13 months- More than double the survival rate of those not receiving Nano-Therm therapyNanotechnology is already commonly used in sunscreen and to make tennis balls more bouncy

- Flu Testing- Today's flu tests are:- Time consuming- Inaccurate- Nanomedicine gold flu testing provides:- Instant results- Immediate treatment cycle to avoid spreading to others- commercial nanotech testing no more than 5 years away- Cell Feedback- Nanomedicine can be used to test cell's response to drugs offering new drug testing methods- Provides instant feedback to how cells respond to medicine- Can save years and millions of dollars on testing and clinical trials- Can improve current medications

In a 1956, Arthur C. Clarke first envisioned the concept of nanotechnology in a short story, The Next TenantsAdvantages of Nanomedicine

- Faster diagnosis of many ailments- More precise treatments of conditions such as cancer- Repair tissue deep within the body- Target only diseased organs, lessening the need for drugsSources

- https://commonfund.nih.gov/nanomedicine/overview.aspx- http://www.understandingnano.com/medicine.html- http://pubs.acs.org/doi/abs/10.1021/nn400630x- http://www.nature.com/nnano/journal/v6/n10/full/nnano.2011.147.html- http://www.dana.org/news/features/detail_bw.aspx?id=35592- http://pubs.rsc.org/en/Content/ArticleLanding/2011/AN/C1AN15303J- http://onlinelibrary.wiley.com/doi/10.1002/smll.201001642/abstract- http://www.clinam.org/benefits.html

Original post:
The Future Of Nano Medicine

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of Application of PRP for Skin rejuvenation; Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue; and Cell Culturing and Expansion in a Laboratory, applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), its hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

About Advancells Group

Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

For more information, visit https://www.advancells.com/

About International Fertility Centre

IFC is Indias leading fertility center under the leadership and guidance of Dr. Rita Bakshi. She along with her solid team of experienced doctors have create a network of 10+ IVF clinics located in India and Nepal. Their services include In-vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Injection (ICSI), Egg Donation, Surrogacy, Blastocyst, Assisted Hatching, Hysteroscopy, Laparoscopy and much more.

For more information, visit https://www.internationalfertilitycentre.com/

Submit your press release

View original post here:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - Business Wire India